Pompe Disease (Type II)
Overview
Plain-Language Overview
Pompe Disease (Type II) is a rare genetic disorder that affects the body's ability to break down a complex sugar called glycogen. This condition primarily impacts the muscles, including the heart and skeletal muscles, leading to muscle weakness and breathing difficulties. It is caused by a deficiency of an important enzyme called acid alpha-glucosidase, which normally helps break down glycogen inside cells. Without this enzyme, glycogen builds up and damages muscle cells, causing progressive symptoms. The disease can present in infancy or later in life, with more severe symptoms in early-onset cases. The heart is often enlarged in infants, while older patients mainly experience muscle weakness. Overall, Pompe Disease affects mobility, breathing, and heart function.
Clinical Definition
Pompe Disease (Type II) is an autosomal recessive lysosomal storage disorder caused by mutations in the GAA gene leading to deficiency of the enzyme acid alpha-glucosidase. This enzyme deficiency results in accumulation of glycogen within lysosomes, primarily affecting cardiac and skeletal muscle cells. The disease manifests as a spectrum from classic infantile-onset with hypertrophic cardiomyopathy, profound hypotonia, and respiratory failure, to late-onset forms with progressive proximal muscle weakness and respiratory insufficiency without significant cardiac involvement. The core pathology is lysosomal glycogen accumulation causing cellular dysfunction and muscle fiber damage. Diagnosis is critical due to the availability of enzyme replacement therapy. The disorder highlights the importance of lysosomal function in muscle metabolism and systemic health.
Inciting Event
No specific external trigger; disease onset is due to inherited deficiency of acid alpha-glucosidase.
Enzyme deficiency leads to gradual glycogen accumulation starting in utero or early infancy.
Symptom onset often follows the natural progression of lysosomal glycogen buildup.
Latency Period
Infantile-onset symptoms typically appear within the first 3 months of life.
Late-onset Pompe disease may present anytime from childhood to adulthood with a variable latency.
Symptom progression correlates with the degree of residual enzyme activity.
Diagnostic Delay
Early symptoms such as hypotonia and cardiomegaly may be misattributed to other neuromuscular diseases.
Lack of awareness of Pompe disease in late-onset cases leads to delayed diagnosis.
Misdiagnosis as muscular dystrophy or other metabolic myopathies due to overlapping features.
Limited access to enzyme assay or genetic testing in some settings delays confirmation.
Clinical Presentation
Signs & Symptoms
Progressive muscle weakness starting in infancy or later childhood/adulthood
Respiratory insufficiency due to diaphragmatic and accessory muscle involvement
Feeding difficulties and failure to thrive in infantile-onset cases
Cardiomyopathy causing heart failure symptoms in infantile form
Exercise intolerance and fatigue in late-onset Pompe disease
History of Present Illness
Progressive muscle weakness starting proximally and involving respiratory muscles.
Feeding difficulties, failure to thrive, and respiratory distress in infantile-onset cases.
Hypertrophic cardiomyopathy causing heart failure symptoms in infants.
Late-onset patients report exertional fatigue, limb-girdle weakness, and respiratory insufficiency.
Gradual loss of motor milestones or decline in physical activity over months to years.
Past Medical History
History of recurrent respiratory infections due to respiratory muscle weakness.
Previous episodes of cardiomyopathy or heart failure in infancy or childhood.
No prior exposure or medication directly causing symptoms; symptoms are due to genetic enzyme deficiency.
Possible history of delayed motor development or hypotonia in infancy.
Family History
Siblings or close relatives with similar muscle weakness or cardiomyopathy.
Consanguineous parents increasing risk of autosomal recessive inheritance.
Family history of early infant death from cardiac or respiratory failure.
Known carriers or diagnosed cases of Pompe disease in the family.
Physical Exam Findings
Proximal muscle weakness predominantly affecting the shoulder and hip girdles
Macroglossia with a large tongue often observed in infantile-onset cases
Cardiomegaly with a loud heart sound due to hypertrophic cardiomyopathy
Hypotonia with decreased muscle tone and diminished deep tendon reflexes
Respiratory distress signs including use of accessory muscles and tachypnea
Diagnostic Workup
Diagnostic Criteria
Diagnosis of Pompe Disease is established by demonstrating deficient acid alpha-glucosidase enzyme activity in blood, fibroblasts, or muscle tissue. Confirmatory diagnosis requires identification of pathogenic mutations in the GAA gene via molecular genetic testing. Muscle biopsy may show lysosomal glycogen accumulation with vacuolar myopathy but is not required if enzyme assay and genetic testing are conclusive. Newborn screening programs often detect low enzyme activity, prompting further confirmatory testing. Elevated creatine kinase levels and characteristic clinical features support the diagnosis but are not definitive.
Pathophysiology
Key Mechanisms
Lysosomal accumulation of glycogen due to deficiency of acid alpha-glucosidase (GAA) enzyme.
Progressive muscle fiber damage caused by glycogen-filled lysosomes disrupting cellular function.
Cardiomyopathy resulting from glycogen deposition in cardiac muscle cells.
Respiratory muscle weakness due to glycogen accumulation in skeletal muscles.
Autophagic buildup contributing to muscle cell dysfunction and degeneration.
| Involvement | Details |
|---|---|
| Organs | Heart is commonly involved with hypertrophic cardiomyopathy in infantile-onset Pompe disease. |
Skeletal muscles throughout the body show progressive weakness and respiratory muscle involvement. | |
Diaphragm weakness contributes to respiratory insufficiency and failure. | |
| Tissues | Skeletal muscle tissue is primarily affected by glycogen accumulation causing weakness and hypotonia. |
Cardiac muscle tissue involvement leads to hypertrophic cardiomyopathy and heart failure in infantile Pompe disease. | |
| Cells | Skeletal muscle cells accumulate glycogen in lysosomes causing progressive muscle dysfunction. |
Cardiomyocytes are affected by glycogen buildup leading to hypertrophic cardiomyopathy in infantile-onset disease. | |
| Chemical Mediators | Acid alpha-glucosidase deficiency causes impaired glycogen degradation and lysosomal glycogen accumulation. |
Creatine kinase levels are often elevated reflecting muscle damage. |
Treatments
Pharmacological Treatments
Alglucosidase alfa
- Mechanism:
Recombinant acid alpha-glucosidase enzyme replacement reduces lysosomal glycogen accumulation in affected tissues.
- Side effects:
Infusion-related reactions
Hypersensitivity
Fever
- Clinical role:
First-line
Non-pharmacological Treatments
Supportive respiratory care including non-invasive ventilation to manage respiratory muscle weakness.
Physical therapy to maintain muscle strength and prevent contractures.
Nutritional support to address feeding difficulties and maintain adequate caloric intake.
Prevention
Pharmacological Prevention
Enzyme replacement therapy (ERT) with recombinant acid alpha-glucosidase to prevent disease progression
No established pharmacological agents for primary prevention in asymptomatic individuals
Supportive medications such as bronchodilators and antibiotics to prevent respiratory complications
Immunomodulatory therapies to reduce antibody formation against ERT in some cases
No vaccines or prophylactic drugs specific to Pompe disease
Non-pharmacological Prevention
Newborn screening programs for early detection and treatment initiation
Regular respiratory therapy including cough assist and pulmonary hygiene
Physical therapy to maintain muscle strength and prevent contractures
Nutritional support to prevent malnutrition and support growth
Avoidance of respiratory infections through hygiene and vaccination
Outcome & Complications
Complications
Respiratory failure from progressive respiratory muscle weakness
Heart failure due to hypertrophic cardiomyopathy in infantile-onset disease
Aspiration pneumonia from impaired swallowing and cough reflex
Motor disability leading to loss of ambulation
Death often from cardiorespiratory complications if untreated
| Short-term Sequelae | Long-term Sequelae |
|---|---|
|
|
Differential Diagnoses
Pompe Disease (Type II) versus McArdle Disease (Type V Glycogen Storage Disease)
Pompe Disease (Type II) | McArdle Disease (Type V Glycogen Storage Disease) |
|---|---|
Autosomal recessive inheritance affecting lysosomal acid alpha-glucosidase | Autosomal recessive inheritance affecting muscle glycogen phosphorylase |
Infantile onset with cardiomyopathy and hypotonia in classic form | Typically presents in adolescence or early adulthood with exercise intolerance |
Markedly elevated creatine kinase and cardiomegaly due to glycogen accumulation | Normal or mildly elevated creatine kinase, no cardiomyopathy |
Deficient acid alpha-glucosidase activity in blood or tissue assay | Deficient muscle glycogen phosphorylase activity on muscle biopsy |
Pompe Disease (Type II) versus Danon Disease
Pompe Disease (Type II) | Danon Disease |
|---|---|
Autosomal recessive inheritance due to GAA mutation | X-linked dominant inheritance due to LAMP2 mutation |
Infantile onset with hypertrophic cardiomyopathy and profound hypotonia | Adolescent males with hypertrophic cardiomyopathy and intellectual disability |
Lysosomal glycogen accumulation without autophagic vacuoles | Accumulation of autophagic vacuoles with sarcolemmal features on muscle biopsy |
Reduced acid alpha-glucosidase enzyme activity | Absent or reduced LAMP2 protein on immunohistochemistry |
Pompe Disease (Type II) versus Mitochondrial Myopathy
Pompe Disease (Type II) | Mitochondrial Myopathy |
|---|---|
Autosomal recessive nuclear gene mutation | Maternal inheritance or sporadic mutations in mitochondrial DNA |
Infantile onset with predominant cardiac and skeletal muscle involvement | Variable onset, often childhood to adulthood with multisystem involvement |
Normal lactate levels, elevated creatine kinase due to muscle damage | Elevated lactate and lactate-to-pyruvate ratio in blood and CSF |
Lysosomal glycogen accumulation without ragged red fibers | Ragged red fibers and cytochrome c oxidase-negative fibers on muscle biopsy |
Pompe Disease (Type II) versus Carnitine Palmitoyltransferase II Deficiency
Pompe Disease (Type II) | Carnitine Palmitoyltransferase II Deficiency |
|---|---|
Infants with progressive muscle weakness and cardiomyopathy | Adolescents or adults with episodic rhabdomyolysis triggered by prolonged exercise or fasting |
Progressive and continuous muscle weakness and cardiomyopathy | Intermittent episodes with symptom-free intervals |
Elevated creatine kinase and glycogen accumulation in muscle | Elevated serum long-chain acylcarnitines during episodes |
Reduced acid alpha-glucosidase activity in blood or tissue | Reduced CPT2 enzyme activity in muscle or fibroblasts |
Pompe Disease (Type II) versus Infantile Hypothyroidism
Pompe Disease (Type II) | Infantile Hypothyroidism |
|---|---|
Infantile onset with cardiomyopathy and muscle weakness | Congenital or early infancy with developmental delay and hypotonia |
Normal thyroid function tests | Elevated TSH and low free T4 levels |
Progressive without enzyme replacement therapy | Improves with thyroid hormone replacement |
Requires enzyme replacement therapy for clinical improvement | Rapid improvement of hypotonia and developmental milestones with levothyroxine |